SAN FRANCISCO, March 07, 2019 – The R Consortium, a Linux Foundation project supporting the R community, today welcomed Genentech as a Gold member. Genentech is the first company in the pharmaceutical industry to join R Consortium and plans to support the community by contributing to pan-industry collaborative projects that further the adoption of R and its application to drug and biomarker discovery, clinical reporting and pharmaceutical data science.
Thousands of statisticians, analysts and scientists worldwide rely on the R language to allow them to analyze, model and visualize large, complex datasets and to create statistical software. In addition, R provides interfaces to other computing platforms, providing users with access to the best computations for understanding data. Interest in the language is growing across industries that rely on statistical computing including, journalism, finance, AI, and now healthcare.
“We are excited to join the R Consortium as a gold member,” said Alun Bedding, director of biostatistics at Genentech, and the Genentech representative for R Consortium. “We see R as the future of statistical analysis because of its flexibility and the strong active community behind it.”
Genentech’s decision to join the R Consortium highlights how the R language is particularly well suited not just to designing clinical trials, but other areas important to the pharmaceutical industry and more broadly, medical research. Some specific examples include; reproducible research, regulatory compliance and validation, safety monitoring, drug discovery, research & development, genomics, diagnostics, PK/PD/pharmacometrics, immunogenicity and more.
“We are pleased to welcome Genentech into the R Consortium family,” said Louis Bajuk, chair of the R Consortium Board of Directors and senior director of product management for streaming and advanced analytics at TIBCO Software. “We see great value in the symbiotic relationship between our organizations as R continues to expand into pharmaceutical data science.”
Genentech joins six existing R Consortium Gold and Platinum members, including: TIBCO, IBM, Gordon and Betty Moore Foundation, Microsoft and RStudio.
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
About The R Consortium
The R Consortium is a 501(c)6 nonprofit organization and Linux Foundation project dedicated to the support and growth of the R user community. The R Consortium provides support to the R Foundation and to the greater R Community for projects that assist R package developers, provide documentation and training, facilitate the growth of the R Community and promote the use of the R language. For more information about R Consortium, please visit: http://www.r-consortium.org.
The Linux Foundation email@example.com